Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3K | 3K | 0 | 0 | 0 |
| Gross Profit | 2K | -6K | 0 | -435K | -435K |
| Operating Income | -248K | -474K | -1M | -753K | -677K |
| EBITDA | -971K | 26K | 194K | -4M | -677K |
| Net Income | -1M | -569K | -875K | -5M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0009
-10.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharmagreen Biotech Inc. (PHBI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of -25.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.7%, EPS -25.0%, free cash flow +62.0% with operating margin -37.5% and ROIC 14.1%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHBI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHBI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHBI Max Drawdown
-80.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHBI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.4M
+46.2% YoY
Free Cash Flow
-$607.6K
-194.9% YoY
Revenue Growth
+13.7%
EPS Growth
-25.0%
Gross Margin
-0.0%
Net Margin
-16.3%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3K | 3K | 0 | 0 | 0 |
| Gross Profit | 2K | -6K | 0 | -435K | -435K |
| Operating Income | -248K | -474K | -1M | -753K | -677K |
| EBITDA | -971K | 26K | 194K | -4M | -677K |
| Net Income | -1M | -569K | -875K | -5M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 276 | 1K | 8K | 25K | 12K |
| Total Assets | 98K | 122K | 209K | 373K | 266K |
| Total Liabilities | 3M | 2M | 2M | 2M | 3M |
| Shareholder Equity | -3M | -2M | -2M | -2M | -3M |
| Total Debt | 356K | 373K | 339K | 270K | 715K |
| Net Debt | 356K | 372K | 331K | 245K | 702K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
608K
-194.9% YoY
Capital Expenditures
0
Free Cash Flow
608K
-194.9% YoY
Key ratios
Gross Margin
-0.0%
Operating Margin
-37.5%
Net Margin
-16.3%
ROE
13.3%
Debt / Equity
-0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.